13726-17-5

Basic information

• Product Name: (4-Chloro-3-Methoxyphenyl)Methanol
• Synonyms: (4-Chloro-3-Methoxyphenyl)Methanol;4-Chloro-3-methoxybenzyl alcohol
• CAS NO: 13726-17-5
• Molecular Formula: C₈H₉ClO₂
• Molecular Weight: 172.60886
• Mol File: 13726-17-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (4-Chloro-3-Methoxyphenyl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Chloro-3-Methoxyphenyl)Methanol(13726-17-5)
• EPA Substance Registry System: (4-Chloro-3-Methoxyphenyl)Methanol(13726-17-5)

Safety Data

• Hazardous Substances Data: 13726-17-5(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 32, p. 1757, 1989 DOI: 10.1021/jm00128a016

Upstream product

• 615-74-7 2-chloro-5-methylphenol 
• 77-78-1 dimethyl sulfate 
• 116022-18-5 methyl 4-chloro-3-methoxybenzoate 
• 85740-98-3 4-chloro-3-methoxybenzoic acid 
• 97-52-9 2-methoxy-4-nitrophenylamine 
• 13726-14-2 4-chloro-m-anisidine 
• 1009-36-5 2-chloro-5-nitroanisole 
• 73909-16-7 2-chloro-5-methylanisole 
• 56962-12-0 3-hydroxy-4-chlorobenzaldehyde 
• 13726-16-4 4-chloro-3-methoxybenzaldehyde 

Downstream Products

• 1350473-74-3 4-(3-(4-chloro-3-methoxyphenyl)-1H-pyrazol-4-yl)pyridine 
• 85740-98-3 4-chloro-3-methoxybenzoic acid 
• 672931-86-1 (4-Chloro-3-hydroxyphenyl) acetic acid methyl ester 
• 915789-03-6 methyl 2-(4-chloro-3-methoxyphenyl)acetate 
• 13726-25-5 3-Methoxy-4-chlor-phenylacetylhomoveratrylamin 
• 13726-19-7 2-(4-chloro-3-methoxyphenyl)acetic acid 
• 13726-21-1 2-(4-chloro-3-methoxyphenyl)acetonitrile 
• 67287-48-3 3-Allyl-6-chloro-1-(4-chloro-3-hydroxy-phenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol; hydrobromide 

Relevant articles and documents

Evaluation of the inhibitory effects of pyridylpyrazole derivatives on lps-induced pge2 productions and nitric oxide in murine raw 264.7 macrophages

A series of thirteen triarylpyrazole analogs were investigated as inhibitors of lipopolysaccharide (LPS)-induced prostaglandin E2 (PGE2 ) and nitric oxide (NO) production in RAW 264.7 macrophages. The target compounds 1a–m have first

PLATELET ADP RECEPTOR INHIBITORS

no abstract published

Preparation of (2E,4E)-2-(2-benzyloxyethyl)-5-(3-methoxy-4-chlorophenyl) penta-2,4-dienal as a key intermediate in the synthesis of strobilurin B

(2E,4E)-2-(2-Benzyloxyethyl)-5-(4-chloro-3-methoxyphenyl)penta-2,4-dienal was obtained by the condensation of 4-benzyloxybutanal N-tert-butylimine with 4-chloro-3-methoxycinnamic aldehyde with ≥98% configurational purity and 40% yield. When 4-benzyloxy-2-triethylsilylbutanal imine was used, a 7: 3 mixture of the target (2E,4E)-dienal with its (2Z,4E)-isomer was obtained in 60% yield; the latter quantitatively isomerized to the thermodynamically preferable target (2E,4E)-dienal.

CHROMENE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of MCP-1 or CCR-2 of formula (I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W1, W2, W3, Y, Z, R2, R3, R3

ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON

A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X3 is COOR17 or the like Y i

Piperidine derivatives and methods of use

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

LIGANDS OF MELANOCORTIN RECEPTORS AND COMPOSITIONS AND METHODS RELATED THERETO

Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I): (I) including stereoisomers, prodrugs, and pharmaceutically acceptable salts thereof, wherein m, n, q, s, R1, R1a, R1b, R2, R3, R4a, R4b, R5a, R5b, X1, X2, X3, X4 and Ar are as defined herein. Pharmaceutical compositions containing a compound of structure (I), as well as methods relating to the use thereof, are also disclosed.

Platelet ADP receptor inhibitors

Novel compounds of formulae (I) to (VIII), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I) to (VIII), or a pharmaceutically acceptable salt thereof.

Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof

Substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts, pharmaceutical compositions containing them, and methods for the treatment of neurodegenerative disorders or neurotoxic injuries utilizing them, wherein the substituted 6,11-ethano-6,11-dihydrobenzo[b]quinolizinium salts have the formula: STR1 wherein: R1, R2, R3, R4, R5, R6, R7, X and p are as defined in the specification.